The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis

Journal of the American Academy of Dermatology

Volumn 63, Issue 3, 2010, Pages 483-489

  Kelly, Brent C ^a   Markle, Leslie Scroggins ^a   Vickers, Jennifer L ^a   Petitt, Matthew S ^a   Raimer, Sharon S ^a   McNeese, Catherine ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Dba Brazos Valley Pathology   (United States)

Author keywords

Matrix metalloproteinase; Myofibroblast; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; Smooth muscle actin; Tissue inhibitor of matrix metalloproteinase; Transforming growth factor

Indexed keywords

ACTIN ANTIBODY; ALPHA SMOOTH MUSCLE ACTIN; ENZYME ANTIBODY; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KELOID; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SKIN BIOPSY; SKIN CULTURE; SKIN SCAR; SPINDLE CELL; STAIN; DISEASE COURSE; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE CULTURE TECHNIQUE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PROGNOSIS; REFERENCE VALUES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE CULTURE TECHNIQUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77955864516     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.09.006     Document Type: Article

References (48)

1. S.E. Cowper, H.S. Robin, and S.M. Steinberg Scleromyxoedema-like cutaneous diseases in renal-dialysis patients Lancet 356 2000 1000 1001
2. T. Grobner Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 2006 1104 1108
3. A.S. Boyd, J.A. Zic, and J.L. Abraham Gadolinium deposition in nephrogenic fibrosing dermopathy J Am Acad Dermatol 56 2007 27 30
4. C. Wiginton, B. Kelly, A. Oto, M. Jesse, and G. Chaljub Nephrogenic Systemic Fibrosis: Association with Gadolinium-Based MR Contrast and Other Risk Factors Am J Roentgeno 190 2008 1060 1068
5. W.W. Ting, M.S. Stone, K.C. Madison, and K. Kurtz Nephrogenic fibrosing dermopathy with systemic involvement Arch Dermatol 139 2003 903 906
6. A. Saenz, R. Mandal, R. Kradin, and E.T. Hedley-Whyte Nephrogenic fibrosing dermopathy with involvement of the dura mater Virchows Archiv 449 2006 389 391
7. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007. Available at: http://www.icnfdr.org. Accessed June 28, 2009.
8. S.E. Cowper, M. Rabach, and M. Girardi Clinical and histologic findings in nephrogenic systemic fibrosis Eur J Radiol 66 2008 191 199
9. T.E. Quan, S. Cowper, S.P. Wu, L.K. Bockenstedt, and R. Bucala Circulating fibrocytes: collagen-secreting cells of the peripheral blood Int J Biochem Cell Biol 36 2004 598 606
10. A. Kreuter, T. Gambichler, S.M. Weiner, and G. Schieren Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis Arch Dermatol 144 2008 1527 1529
11. K. Mathur, S. Morris, C. Deighan, R. Green, and K.W. Douglas Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: three case reports and review of literature J Clin Apher 23 2008 144 150
12. S. Chandran, J. Petersen, C. Jacobs, D. Fiorentino, K. Doeden, and R.A. Lafayette Imatinib in the treatment of nephrogenic systemic fibrosis Am J Kidney Dis 53 2009 129 132
13. W.A. High, R.A. Ayers, J. Chandler, G. Zito, and S.E. Cowper Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis J Am Acad Dermatol 56 2007 21 26
14. B. Kelly, M. Petitt, and R. Sanchez Nephrogenic fibrosing dermopathy is associated with TGF-β and SMAD2/3 without evidence of renin-angiotensin involvement J Am Acad Dermatol 58 2008 1025 1030
15. S. Jiménez, C. Artlett, N. Sandorfi, C. Derk, K. Latinis, and H. Sawaya Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin Arthritis Rheum 50 2004 2660 2666
16. J.A. Gillard, M.W. Reed, D. Buttle, S.S. Cross, and N.J. Brown Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing Wound Repair Regen 12 2004 295 304
17. T.Z. Kirk, M.E. Mark, C.C. Chua, B.H. Chua, and M.D. Mayes Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1 J Biol Chem 270 1995 3423
18. K. Kikuchi, M. Kubo, and S. Sato Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis J Am Acad Dermatol 33 1995 973
19. G. Bou-Gharios, J. Osman, C. Black, and I. Olsen Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis Clin Chim Acta 231 1994 69
20. C.P. Denton, and D.J. Abraham Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis Curr Opin Rheumatol 13 2001 505 511
21. S.J. Chen, W. Yuan, Y. Mori, A. Levenson, M. Trojanowska, and J. Varga Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of SMAD3 J Invest Dermatol 112 1999 49 57
22. W. Yuan, and J. Varga Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3 J Biol Chem 276 2001 38502 38510
23. D.R. Edwards, G. Murphy, J.J. Reynolds, S.E. Whitham, A.J. Docherty, and P. Angel Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor EMBO J 6 1987 1899 1904
24. A. Sappino, I. Masouyé, J. Saurat, and G. Gabbiani Smooth muscle differentiation in scleroderma fibroblastic cells Am J Pathol 1990 137 585-91
25. E.Y. Kissin, P.A. Merkel, and R. Lafyatis Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis Arthritis Rheum 54 2006 3655 3660
26. K.M. Hong, J.A. Belperio, M.P. Keane, M.D. Burdick, and R.M. Strieter Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor γ J Biol Chem 282 2007 22910 22920
27. A. Leask Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma Cell Signal 20 2008 1409 1414
28. R. Yamaguchi, Y. Takami, Y. Yamaguchi, and S. Shimazaki Bone marrow-derived myofibroblasts recruited to the upper dermis appear beneath regenerating epidermis after deep dermal burn injury Wound Repair Regen 15 2007 87 93
29. S.D. Shapiro Matrix metalloproteinase degradation of extracellular matrix: biological consequences Curr Opin Cell Biol 10 1998 602 608
30. I. Pucci-Minafra, S. Minafra, G. La Rocca, M. Barranca, S. Fontana, and G. Alaimo Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis Matrix Biol 2 2001 419 427
31. T. Yamamoto, and K. Nishioka Animal Model of Sclerotic Skin. V: Increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma Clin Immunol 102 2002 77 83
32. A. Desmouliere, C. Chaponnier, and G. Gabbiani Tissue repair, contraction, and the myofibroblast Wound Repair Regen 13 2005 7 12
33. J.I. Virag, and C.E. Murry Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair Am J Pathol 163 2003 2433 2440
34. V.J. Thannickal, G.B. Toews, E.S. White, J.P. Lynch III, and F.J. Martinez Mechanisms of pulmonary fibrosis Annu Rev Med 55 2004 395 417
35. H.Y. Lan Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells Curr Opin Nephrol Hypertens 12 2003 25 29
36. S. Tanriverdi-Akhisaroglu, A. Menderes, and G. Oktay Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study Cell Biochem Funct 27 2009 81 87
37. M. Edward, J.A. Quinn, S. Mukherjee, M.B. Jensen, A.G. Jardine, and P.B. Mark Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis J Pathol 214 2008 584 593
38. M. Plotkin, and V. Mudinuri Pod1 induces myofibroblast differentiation in mesenchymal progenitor cells from mouse kidney J Cell Biochem 103 2008 675 690
39. S. Mizuno, K. Matsumoto, M.Y. Li, and T. Nakamura HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis FASEB J 19 2005 580 582
40. K. Higashi, Y. Inagaki, K. Fujimori, A. Nakao, H. Kaneko, and I. Nakatsuka Interferon gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3 J Biol Chem 278 2003 43470 43479
41. Y. Akasaka, I. Ono, A. Tominaga, Y. Ishikawa, K. Ito, and T. Suzuki Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of α-smooth muscle actin, leading to reduction of wound contraction Wound Rep Regen 15 2007 378 389
42. B. Hinz Formation and function of the myofibroblast during tissue repair J Invest Dermatol 127 2007 526 537
43. A.B. Kulkarni, and S. Karlsson Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease Am J Pathol 143 1993 3 9
44. E.P. Bottinger, J.J. Letterio, and A.B. Roberts Biology of TGF-beta in knockout and transgenic mouse models Kidney Int 51 1997 1355 1360
45. J. Larsson, M. Goumans, L. Sjostrand, M. van Rooijen, D. Ward, and P. Leveen Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice EMBO J 20 2001 1663 1673
46. X. Yang, J.J. Letterio, R.J. Lechleider, L. Chen, R. Hayman, and H. Gu Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta EMBO J 18 1999 1280 1291
47. A.J. Borton, J.P. Frederick, M.B. Datto, X.F. Wang, and R.S. Weinstein The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis J Bone Mineral Res 16 2001 1754 1764
48. Q.-H. Nie, C.-L. Zhu, Y.-F. Zhang, J. Yang, J.C. Zhang, and R.T. Gao Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis Dig Dis Sci 2009 June 11 Epub ahead of print